Bliss Biopharmaceutical Co., Ltd announced a clinical trial collaboration agreement with option for strategic collaboration with Eisai Co., Ltd., for BB-1701, eribulin-payload based ADC directed against Human Epidermal Growth Factor Receptor 2 for the treatment of cancers.
